Cirsiliol Alleviates Experimental Inflammatory Bowel Disease via Restoration of Intestinal Barrier Integrity and Inhibition of NF-κB and MAPK Pathways
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 8, 2025
Abstract
Inflammatory
bowel
disease
(IBD)
is
a
chronic
gastrointestinal
disorder
characterized
by
intestinal
inflammation
and
barrier
dysfunction.
This
study
investigated
the
therapeutic
potential
of
Cirsiliol,
natural
flavonoid,
in
DNBS-induced
murine
colitis
model..Mice
were
randomly
divided
into
control,
model,
Cirsiliol
treatment
groups
(10
mg/kg
30
mg/kg).
Disease
activity
was
assessed
through
body
weight,
colon
length,
index
(DAI).
Molecular
mechanisms
evaluated
using
immunohistochemistry,
Western
blot,
biochemical
assays.
significantly
ameliorated
symptoms,
reducing
weight
loss
DAI
scores
while
improving
length.
Mechanistically,
suppressed
pro-inflammatory
cytokines
(TNF-α,
IL-6,
IL-1β),
enhanced
antioxidant
defenses
(increased
GSH,
decreased
MDA),
restored
tight
junction
protein
expression
(Claudin-1,
Occludin,
E-cadherin).
Furthermore,
it
modulated
apoptosis-related
proteins
(reduced
Bax,
Caspase-3;
increased
Bcl-2)
promoted
epithelial
migration.
Language: Английский
Prebiotics in food and dietary supplements: a roadmap to EU health claims
Kieran Tuohy,
No information about this author
Elaine E. Vaughan,
No information about this author
Lucien F. Harthoorn
No information about this author
et al.
Gut Microbes,
Journal Year:
2024,
Volume and Issue:
16(1)
Published: Nov. 15, 2024
Numerous
studies
have
established
that
prebiotic
ingredients
in
foods
and
dietary
supplements
may
play
a
role
supporting
human
health.
Over
the
three
decades
passed
since
prebiotics
were
first
defined
as
concept,
research
has
revealed
complex
universe
of
prebiotic-induced
changes
to
microbiota.
There
are
strong
indications
direct
link
between
these
specific
health
benefits.
However,
at
present
time,
EU
not
permitted
use
term
'prebiotic'
connection
with
an
approved
claim.
This
paper
is
outcome
workshop
organized
on
25th
October
2023
by
European
branch
International
Life
Science
Institute
(ILSI).
It
provides
overview
regulatory
requirements
for
authorized
claims
EU,
key
areas
research,
findings
date
relation
digestive,
immune,
metabolic
cognitive
Research
gaps
documentation
challenges
then
explored
roadmap
proposed
achieving
authorization
wording
future
claims.
Language: Английский